Assessment of Programmed Cell Death Protein ۱ and Programmed Cell Death Ligand ۱ Expression in Gestational Trophoblastic Neoplasia: Implications for Anti-PD۱ Drug Therapy

Background and Aims: This study was done to assess the levels of Programmed cell death ۱ (PD-۱) and its ligands (PD-L۱) expression in gestational trophoblastic neoplasia (GTN) to determine the outcome of prescribing anti PD-۱ drugs in trophoblastic tumors.Methods: This study was conducted in the gynecology oncology clinic of Mashhad medical science university in the north-east of Iran during ۲۰۱۲-۲۰۲۲. The patients were divided into two groups consist of low-risk and high-risk groups based on their International Federation of Gynecology and Obstetrics (FIGO) score, and subsequently their response to the chemotherapy was evaluated. We scored PD-L۱ staining in tumor cells using a ۴-point scoring system and evaluated PDL-۱ expression using the Allered Total Score (ATS).Results: ۵۲ GTN patients with a mean age of ۲۷ were undergone in our study between. Out of all patients in our study, ۴۷ and ۵ patients were diagnosed by molar pregnancy and choriocarcinoma, respectively. The patients with molar pregnancy were also sub grouped into ۲۲ (۴۲.۳%) patients and ۲۵ (۴۸.۱%) patients with complete hydatidiform mole (CHM) and partial hydatidiform mole (PHM). The results of PDL-۱ staining intensity showed ۳ (۵.۸%), ۱۲ (۲۳.۱%), ۲۷ (۵۱.۹%), and ۱۰ (۱۹.۲%) were No, weak, moderate, and strong staining, respectively.Conclusion: The findings of this present study indicated that the high-level PD-L۱ expression in the majority of our patients. Seem to suggest the potential use of immune checkpoint inhibition as a treatment option for trophoblastic tumors, which deserves further comprehensive study through clinical trials.

کلیدواژه ها:

Gestational trophoblastic diseases ، Programmed cell death ligand ۱ ، programmed death receptor ۱ ، Trophoblastic tumors ، immunohistochemistry (IHC) staining